Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers

TIR index is a feasible approach for assessing tumor-specific TCR and stratifying NSCLC patients for anti-PD-(L)1 therapy.